EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Angiotensin Receptor and Neprilysin Inhibitors in CKD

Antonio De Pascalis, Alessandro Tomassetti iD, Daniele Vetrano iD, Massimo Iacoviello iD, Stefania Marazia iD, Alessandro Fucili, Edoardo Tringali iD, Gaetano La Manna iD, Giuseppe Cianciolo iD

Kidney360 · 2026-08 · 7 (8) · 1900-1908

DOI: 10.34067/kid.0000001122 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney360, online erschienen am 07.01.2026. Verfasst von Antonio De Pascalis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Dialysis, and Renal Transplantation Unit, Vito Fazzi Hospital, Lecce, Italy. Hauptthemen laut MEDLINE: Neprilysin, Angiotensin Receptor Antagonists, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combined inhibition of neprilysin (NEP) and the angiotensin II receptor through angiotensin receptor–neprilysin inhibitors (ARNIs) has transformed heart failure management and is garnering increasing attention in nephrology. This article explores the renal role of NEP and critically reviews preclinical and clinical evidence on the use of ARNIs in CKD, following a bench-to-bedside approach. Experimental data show that NEP inhibition improves proteinuria, fibrosis, and endothelial function, with enhanced benefits when combined with renin-angiotensin-aldosterone system blockade. Randomized clinical trials in patients with heart failure (HF) (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor With Angiotensin Converting Enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF], Prospective Comparison Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin-Receptor Blockers Global Outcomes in Heart Failure with Preserved Ejection Fraction [PARAGON-HF], Prospective comparison of Angiotensin Receptor–neprilysin inhibitor with Angiotensin-Receptor Blockers Given following stabiLization In DEcompensated Heart Failure with preserved ejection fraction [PARAGLIDE-HF]) have demonstrated renal safety and potential benefit emerged in secondary end points and prespecified analysis. The only randomized clinical trial performed with primary kidney outcome, the UK Heart and Renal Protection III (HARP-III) trial, confirmed the tolerability of sacubitril/valsartan, and reported a significant reduction in proteinuria. No clear nephroprotective effect was observed; however, the trial design may not have been adequately structured to detect such an effect. On the other hand, real-world data indicate that ARNIs have an acceptable risk profile when patients are appropriately monitored, as renin-angiotensin-aldosterone system blockers. Moreover, the benefits of the treatment clearly outweigh the adverse effects. Therefore, sacubitril/valsartan may emerge as a promising therapeutic option in nephrology, especially in patients with cardiorenal disease, pending further trials to better define its role in CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeprilysinAngiotensin Receptor AntagonistsRenal Insufficiency, ChronicHumansHeart FailureAnimalsAminobutyratesBiphenyl CompoundsValsartanTetrazolesRandomized Controlled Trials as TopicKidneyRenin-Angiotensin SystemDrug Combinations

Stichwörter der Autor:innen

CKDcardiorenal syndrome

Substanzen

NeprilysinAngiotensin Receptor AntagonistsAminobutyratesBiphenyl CompoundsValsartanTetrazolessacubitril and valsartan sodium hydrate drug combinationDrug Combinations

Autor:innen und Institutionen

  • Nephrology, Dialysis, and Renal Transplantation Unit, Vito Fazzi Hospital, Lecce, Italy.
  • Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Department of Cardiovascular Medicine, Ospedale V Fazzi, ASL Lecce, Lecce, Italy.
  • Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
  • Nephrology and Dialysis Unit, ASL TO4, Turin, Italy.

ORCID-Profile: Alessandro Tomassetti, Daniele Vetrano, Massimo Iacoviello, Stefania Marazia, Edoardo Tringali, Gaetano La Manna, Giuseppe Cianciolo

Zitieren

APA

De Pascalis, A., Tomassetti, A., Vetrano, D., Iacoviello, M., Marazia, S., Fucili, A., Tringali, E., La Manna, G., & Cianciolo, G. (2026). Angiotensin Receptor and Neprilysin Inhibitors in CKD. Kidney360, 7(8), 1900-1908. https://doi.org/10.34067/kid.0000001122

Vancouver

De Pascalis A, Tomassetti A, Vetrano D, Iacoviello M, Marazia S, Fucili A, et al. Angiotensin Receptor and Neprilysin Inhibitors in CKD. Kidney360. 2026;7(8):1900-1908. doi:10.34067/kid.0000001122

BibTeX
@article{DePascalis2026,
  author = {De Pascalis, Antonio and Tomassetti, Alessandro and Vetrano, Daniele and Iacoviello, Massimo and Marazia, Stefania and Fucili, Alessandro and Tringali, Edoardo and La Manna, Gaetano and Cianciolo, Giuseppe},
  title = {Angiotensin Receptor and Neprilysin Inhibitors in CKD},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {8},
  pages = {1900--1908},
  doi = {10.34067/kid.0000001122}
}
Kostenlos starten →